441 related articles for article (PubMed ID: 19896533)
1. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
Zupan J; Mencej-Bedrac S; Jurković-Mlakar S; Prezelj J; Marc J
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
[TBL] [Abstract][Full Text] [Related]
2. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
3. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density.
Mencej-Bedrac S; Prezelj J; Kocjan T; Teskac K; Ostanek B; Smelcer M; Marc J
J Mol Endocrinol; 2009 Mar; 42(3):239-47. PubMed ID: 19131500
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.
Mencej-Bedrač S; Zupan J; Mlakar SJ; Zavratnik A; Preželj J; Marc J
Drug Metabol Drug Interact; 2014; 29(2):111-4. PubMed ID: 24615483
[TBL] [Abstract][Full Text] [Related]
5. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
[TBL] [Abstract][Full Text] [Related]
6. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women.
Mencej-Bedrač S; Preželj J; Marc J
Maturitas; 2011 Jul; 69(3):263-7. PubMed ID: 21411255
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.
Shang M; Lin L; Cui H
Clin Biochem; 2013 Oct; 46(15):1493-501. PubMed ID: 23531404
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women.
Tu P; Duan P; Zhang RS; Xu DB; Wang Y; Wu HP; Liu YH; Si L
Osteoporos Int; 2015 Jan; 26(1):179-85. PubMed ID: 25138264
[TBL] [Abstract][Full Text] [Related]
9. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis.
Mencej S; Albagha OM; Prezelj J; Kocjan T; Marc J
J Mol Endocrinol; 2008 Jun; 40(6):273-9. PubMed ID: 18502820
[TBL] [Abstract][Full Text] [Related]
11. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women.
Markatseli AE; Hatzi E; Bouba I; Georgiou I; Challa A; Tigas S; Tsatsoulis A
Maturitas; 2011 Oct; 70(2):188-93. PubMed ID: 21840657
[TBL] [Abstract][Full Text] [Related]
12. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
[TBL] [Abstract][Full Text] [Related]
13. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men.
Roshandel D; Holliday KL; Pye SR; Boonen S; Borghs H; Vanderschueren D; Huhtaniemi IT; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC; Thomson W; O'Neill TW;
J Bone Miner Res; 2010 Aug; 25(8):1830-8. PubMed ID: 20205168
[TBL] [Abstract][Full Text] [Related]
15. Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression.
Takács I; Lazáry A; Kósa JP; Kiss J; Balla B; Nagy Z; Bácsi K; Speer G; Lakatos P
Eur J Endocrinol; 2010 Feb; 162(2):423-31. PubMed ID: 19934266
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor gene polymorphisms and bone mineral density in Korean postmenopausal women.
Woo JH; Kim H; Kim JH; Kim JG
Menopause; 2015 May; 22(5):512-9. PubMed ID: 25268406
[TBL] [Abstract][Full Text] [Related]
17. Testing GSTP1 genotypes and haplotypes interactions in Slovenian post-/pre-menopausal women: novel involvement of glutathione S-transferases in bone remodeling process.
Mlakar SJ; Prezelj J; Marc J
Maturitas; 2012 Feb; 71(2):180-7. PubMed ID: 22221655
[TBL] [Abstract][Full Text] [Related]
18. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
19. Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women.
Mencej S; Prezelj J; Kocijancic A; Ostanek B; Marc J
Maturitas; 2006 Oct; 55(3):219-26. PubMed ID: 16730419
[TBL] [Abstract][Full Text] [Related]
20. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
